Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6000128 | 0.83 | NPC1 (0.61) | RAB9ANPC1HDAC6KDM4EHSD17B10 | |
| SCHEMBL11431402 | 0.82 | POLB (0.52) | KDM4EHSD17B10ALDH1A1HPGDHTT | |
| SCHEMBL9262855 | 0.82 | SMN1; SMN2 (0.65) | RAB9ANPC1HDAC6KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL6000120 | 0.82 | NPC1 (0.60) | RAB9ANPC1HDAC6KDM4EHSD17B10 | |
| SCHEMBL17933571 | 0.80 | HDAC6 (0.72) | RAB9ANPC1HDAC6KDM4EALDH1A1 | |
| SCHEMBL7069710 | 0.80 | HPGD (0.48) | RAB9ANPC1HDAC6KDM4EHSD17B10 | |
| SCHEMBL17380973 | 0.80 | POLB (0.58) | RAB9AKDM4EHSD17B10ALDH1A1HTT | |
| SCHEMBL7978871 | 0.80 | AKT1 (0.42) | RAB9ANPC1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL13649430 | 0.79 | HDAC6 (0.61) | RAB9ANPC1HDAC6KDM4EALDH1A1 | |
| SCHEMBL9675374 | 0.79 | AKR1B1 (0.76) | KDM4EALDH1A1MEN1KMT2ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114573604-B | Quinolone-based compound, preparation method thereof, pharmaceutical composition containing quinolone-based compound and application of quinolone-based compound | 中国科学院上海药物研究所 | 2024-06-18 | — | — | CN | disclosed |
| CN-113597547-B | Fluorescent imaging agent for lipid droplets in cells and tissues | 国立大学法人群马大学 | 2024-04-30 | — | — | CN | disclosed |
| CN-113597547-A | Fluorescent imaging agent for lipid droplets in cells and tissues | 国立大学法人群马大学 | 2021-11-02 | — | — | CN | disclosed |
| US-10590134-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20180079750-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2018-03-22 | — | — | US | disclosed |
| EP-0972769-B1 | NOVEL AMIDE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | YAMANOUCHI PHARMA CO LTD (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-6177454-B1 | ANTIDIABETIC AGENTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2001-01-23 | — | — | US | disclosed |
| US-6048884-A | ANTIDIABETIC AGENTS; HYPOGLYCEMIC AGENTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2000-04-11 | — | — | US | disclosed |
| EP-0972769-A1 | NOVEL AMIDE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2000-01-19 | — | — | EP | disclosed |
| US-4003750-A | METHINE DYES | EASTMAN KODAK COMPANY (US) | 1977-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590134-B2 | Compositions, uses and methods for making them | BAX, CASP3, BCL2 | RAB9A 3371/4885NPC1 1273/4885HDAC6 457/4885 |
| US-20180079750-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, BCL2 | RAB9A 3102/4885NPC1 1234/4885HDAC6 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.